Emerging nanoparticle platforms for CpG oligonucleotide delivery

被引:9
|
作者
Li, Mingqiang [1 ]
Yao, Haochen [2 ]
Yi, Ke [1 ]
Lao, Yeh-Hsing [3 ]
Shao, Dan [4 ]
Tao, Yu [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Ctr Nanomed, Lab Biomat & Translat Med, Guangzhou 510630, Peoples R China
[2] First Hosp Jilin Univ, Gen Surg Ctr, Hepatobiliary & Pancreat Surg Dept, 1 Xinmin St, Changchun 130021, Jilin, Peoples R China
[3] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14214 USA
[4] South China Univ Technol, Sch Biomed Sci & Engn, Inst Life Sci, Guangzhou 510006, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
METAL-ORGANIC-FRAMEWORK; MESOPOROUS SILICA NANOPARTICLES; CALCIUM-PHOSPHATE NANOPARTICLES; PLASMACYTOID DENDRITIC CELLS; POLYMERIC HYBRID MICELLES; ENHANCED IMMUNE-RESPONSE; TOLL-LIKE RECEPTOR-9; CO-DELIVERY; IN-VIVO; GOLD NANOPARTICLES;
D O I
10.1039/d3bm01970e
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Unmethylated cytosine-phosphate-guanine (CpG) oligodeoxynucleotides (ODNs), which were therapeutic DNA with high immunostimulatory activity, have been applied in widespread applications from basic research to clinics as therapeutic agents for cancer immunotherapy, viral infection, allergic diseases and asthma since their discovery in 1995. The major factors to consider for clinical translation using CpG motifs are the protection of CpG ODNs from DNase degradation and the delivery of CpG ODNs to the Toll-like receptor-9 expressed human B-cells and plasmacytoid dendritic cells. Therefore, great efforts have been devoted to the advances of efficient delivery systems for CpG ODNs. In this review, we outline new horizons and recent developments in this field, providing a comprehensive summary of the nanoparticle-based CpG delivery systems developed to improve the efficacy of CpG-mediated immune responses, including DNA nanostructures, inorganic nanoparticles, polymer nanoparticles, metal-organic-frameworks, lipid-based nanosystems, proteins and peptides, as well as exosomes and cell membrane nanoparticles. Moreover, future challenges in the establishment of CpG delivery systems for immunotherapeutic applications are discussed. We expect that the continuously growing interest in the development of CpG-based immunotherapy will certainly fuel the excitement and stimulation in medicine research. In this review, we provide a comprehensive summary of the nanoparticle-based CpG delivery systems developed to improve the efficacy of CpG-mediated immune responses.
引用
收藏
页码:2203 / 2228
页数:26
相关论文
共 50 条
  • [21] Self-Assembled DNA Dendrimer Nanoparticle for Efficient Delivery of Immunostimulatory CpG Motifs
    Qu, Yijiao
    Yang, Juanjuan
    Zhan, Pengfei
    Liu, Shaoli
    Zhang, Kun
    Jiang, Qiao
    Li, Can
    Ding, Baoquan
    ACS APPLIED MATERIALS & INTERFACES, 2017, 9 (24) : 20324 - 20329
  • [22] An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer
    Lin, Yang
    Chen, Xuehua
    Wang, Ke
    Liang, Li
    Zhang, Hongxia
    VACCINES, 2024, 12 (07)
  • [23] Blood-vessel-on-a-chip Platforms for Evaluating Nanoparticle Drug Delivery Systems
    Li, Yuancheng
    Zhu, Kai
    Liu, Xiao
    Zhang, Yu Shrike
    CURRENT DRUG METABOLISM, 2018, 19 (02) : 100 - 109
  • [24] Peptide-conjugated Nanoparticle Platforms for Targeted Delivery, Imaging, and Biosensing Applications
    Ilies, Bogdan Dragos
    Yildiz, Ibrahim
    Abbas, Manzar
    CHEMBIOCHEM, 2024, 25 (10)
  • [25] Ultrasmall silica nanoparticle platforms for improved small molecular inhibitor delivery and efficacy
    Madajewski, Brian
    Chen, Feng
    Yoo, Barney
    Ma, Kai
    Turker, Melik
    Zhang, Li
    Zanzonico, Pat
    Wiesner, Ulrich
    Bradbury, Michelle
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [26] Delivery of shRNA using gold nanoparticle-DNA oligonucleotide conjugates as a universal carrier
    Ryou, Sang-Mi
    Kim, Sudeok
    Jang, Hyun Hye
    Kim, Jae-Hong
    Yeom, Ji-Hyun
    Eom, Min Sik
    Bae, Jeehyeon
    Han, Min Su
    Lee, Kangseok
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 398 (03) : 542 - 546
  • [27] CpG oligonucleotide as an adjuvant for the treatment of prostate cancer
    Lubaroff, David M.
    Karan, Dev
    ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (03) : 268 - 274
  • [28] Optimization, Production, and Characterization of a CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen
    Milley, Bob
    Kiwan, Radwan
    Ott, Gary S.
    Calacsan, Carlo
    Kachura, Melissa
    Campbell, John D.
    Kanzler, Holger
    Coffman, Robert L.
    BIOCONJUGATE CHEMISTRY, 2016, 27 (05) : 1293 - 1304
  • [29] Self-Assembly of Poly-Adenine-Tailed CpG Oligonucleotide-Gold Nanoparticle Nanoconjugates with Immunostimulatory Activity
    Chen, Nan
    Wei, Min
    Sun, Yanhong
    Li, Fan
    Pei, Hao
    Li, Xiaoming
    Su, Shao
    He, Yao
    Wang, Lianhui
    Shi, Jiye
    Fan, Chunhai
    Huang, Qing
    SMALL, 2014, 10 (02) : 368 - 375
  • [30] Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases
    Mehta, Meenu
    Deeksha
    Tewari, Devesh
    Gupta, Gaurav
    Awasthi, Rajendra
    Singh, Harjeet
    Pandey, Parijat
    Chellappan, Dinesh Kumar
    Wadhwa, Ridhima
    Collet, Trudi
    Hansbro, Philip M.
    Kumar, S. Rajesh
    Thangavelu, Lakshmi
    Negi, Poonam
    Dua, Kamal
    Satija, Saurabh
    CHEMICO-BIOLOGICAL INTERACTIONS, 2019, 308 : 206 - 215